TSCAN THERAPEUTICS INC (TCRX) Stock Income Statement
NASDAQ:TCRX - Nasdaq - US89854M1018 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.42M | 2.82M | 21.05M | 13.54M | 10.14M | |||
| Operating Expenses | 144.12M | 137.64M | 114.51M | 80.17M | 58.78M | |||
| Research and Development | 112.28M | 107.35M | 88.15M | 59.82M | 44.95M | |||
| Selling, General, and Administrative Expenses | 31.84M | 30.29M | 26.35M | 20.35M | 13.83M | |||
| Operating Income | -139.70M | -134.82M | -93.46M | -66.64M | -48.64M | |||
| Interest Income/Expense | 9.30M | 8.41M | 4.24M | 420.00K | 20.00K | |||
| Non Recurring Items | N/A | -1.09M | N/A | N/A | N/A | |||
| Income Before Taxes | -131.48M | -127.50M | -89.22M | -66.22M | -48.63M | |||
| Net Income | -131.48M | -127.50M | -89.22M | -66.22M | -48.63M | |||
| EBITDA | -136.17M | -130.71M | -88.10M | -61.50M | -45.31M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.09 | -1.14 | -1.36 | -2.75 | -2.06 | |||
| Non GAAP EPS | -1.09 | -1.15 | -1.89 | -2.75 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -2974.08% | -4527.66% | -423.86% | -489.07% | -479.59% | |||
| Operating Profit Margin | -3159.87% | -4787.68% | -444.00% | -492.17% | -479.68% | |||
All data in USD